Observational studyThe Journal of international medical research2025
Systemic anticoagulation in progressive chronic kidney disease and atrial fibrillation.
Observational study in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ObjectivePatients with chronic kidney disease are at high risk of developing atrial fibrillation. However, it remains unclear whether systemic anticoagulants should be utilized, particularly in the later stages of chronic kidney disease.MethodsThis retrospective observational cohort study included patients with chronic kidney disease of various etiologies. This study aimed to record the prevalence of atrial fibrillation, use of systemic anticoagulation, and incidence of thromboembolic events and bleeding events among these patients.ResultsA total of 146 patients with chronic kidney disease were included in this study, with 43.8% of them experiencing atrial fibrillation. There was no significant difference in the prevalence of atrial fibrillation across various stages of chronic kidney disease. Thromboembolic events were not common in patients with atrial fibrillation but were prevalent in those with late-stage chronic kidney disease. Furthermore, patients with atrial fibrillation experienced a higher frequency of bleeding events, with the highest incidence observed in chronic kidney disease stage IV.ConclusionsAs systemic anticoagulation did not lower the frequency of thromboembolic events in patients with chronic kidney disease and atrial fibrillation in our study and considering that these patients experienced a higher frequency of bleeding complications, the use of systemic anticoagulants should be approached with caution, particularly in the later stages of chronic kidney disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.